Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Steele, Lynette ^a   Errington, Fiona ^a   Prestwich, Robin ^a   Ilett, Elizabeth ^a   Harrington, Kevin ^b   Pandha, Hardev ^c   Coffey, Matt ^d   Selby, Peter ^a   Vile, Richard ^a,e   Melcher, Alan ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d ONCOLYTICS BIOTECH INC   (Canada)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; CD69 ANTIGEN; CHEMOKINE; CYTOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; ONCOLYTIC VIRUS; PROTEIN KINASE R; RANTES; SMALL INTERFERING RNA; AUTACOID;

ADAPTIVE IMMUNITY; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MEDIATOR RELEASE; MELANOMA CELL; NATURAL KILLER CELL; ONCOLYTIC VIROTHERAPY; PHENOTYPE; PROTEIN EXPRESSION; REOVIRUS; TUMOR IMMUNITY; UPREGULATION; BIOSYNTHESIS; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; IMMUNITY; IMMUNOLOGY; MELANOMA; METABOLISM; REOVIRUS INFECTION; SECRETION; TUMOR CELL LINE; VIROLOGY;

ORTHOREOVIRUS;

ADAPTIVE IMMUNITY; CELL LINE, TUMOR; CHEMOKINES; CHEMOTAXIS; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; EIF-2 KINASE; HUMANS; IMMUNITY; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MELANOMA; NF-KAPPA B; PHENOTYPE; REOVIRIDAE; REOVIRIDAE INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79952361112     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-20     Document Type: Article

References (46)

1. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, Debono JS. A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer. Clin Cancer Res 2008, 14:7127-7137. 10.1158/1078-0432.CCR-08-0524, 18981012.
2. Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, et al. Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers. Clin Cancer Res 2010,
3. Thirukkumaran CM, Nodwell MJ, Hirasawa K, Shi ZQ, Diaz R, Luider J, Johnston RN, Forsyth PA, Magliocco AM, Lee P, et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 2010, 70:2435-2444. 10.1158/0008-5472.CAN-09-2408, 20215509.
4. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998, 282:1332-1334. 10.1126/science.282.5392.1332, 9812900.
5. Song L, Ohnuma T, Gelman IH, Holland JF. Reovirus infection of cancer cells is not due to activated Ras pathway. Cancer Gene Ther 2008,
6. van Houdt WJ, Smakman N, van den Wollenberg DJ, Emmink BL, Veenendaal LM, van Diest PJ, Hoeben RC, Borel IH, Kranenburg O. Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles. Cancer Gene Ther 2008,
7. Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 2008,
8. Benencia F, Courreges MC, Conejo-Garcia JR, Mohamed-Hadley A, Zhang L, Buckanovich RJ, Carroll R, Fraser N, Coukos G. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005,
9. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 2002, 21:85-93.
10. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 2008, 8:1581-1588. 10.1586/14737140.8.10.1581, 2729453, 18925850.
11. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, de Bono J, Selby P, Coffey M, Vile R, Melcher A. Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity. J Immunol 2008, 180:6018-6026.
12. Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008, 14:7358-7366. 10.1158/1078-0432.CCR-08-0831, 2701231, 19010851.
13. Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, et al. Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication. Clin Cancer Res 2009,
14. Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 2009, 183:4312-4321. 10.4049/jimmunol.0901074, 19734207.
15. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242. 10.1146/annurev.immunol.18.1.217, 10837058.
16. Mantovani A. Chemokines. Introduction and overview. Chem Immunol 1999, 72:1-6. full_text, 10550926.
17. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002, 13:143-154. 10.1016/S1359-6101(01)00033-8, 11900990.
18. Paoletti S, Petkovic V, Sebastiani S, Danelon MG, Uguccioni M, Gerber BO. A rich chemokine environment strongly enhances leukocyte migration and activities. Blood 2005, 105:3405-3412. 10.1182/blood-2004-04-1648, 15546958.
19. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 2008, 68:8437-8445. 10.1158/0008-5472.CAN-08-1440, 18922917.
20. Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, Mayer ME, Knaus WA, Mullins DW. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004, 64:7697-7701. 10.1158/0008-5472.CAN-04-2059, 15520172.
21. Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M, O'Donnell D, Selby P, Vile R, Melcher A. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 2006, 13:138-149. 10.1038/sj.gt.3302609, 16136162.
22. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89:1-47. 10.1099/vir.0.83391-0, 18089727.
23. Hogan SP. Recent advances in eosinophil biology. Int Arch Allergy Immunol 2007, 143(Suppl 1):3-14. 10.1159/000101398, 17541270.
24. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000, 88:1544-1548. 10.1002/(SICI)1097-0142(20000401)88:7<1544::AID-CNCR7c3.0.CO;2-S, 10738211.
25. Luster AD, Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993, 178:1057-1065. 10.1084/jem.178.3.1057, 2191174, 8350046.
26. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999, 17:189-220. 10.1146/annurev.immunol.17.1.189, 10358757.
27. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002, 14:432-436. 10.1016/S0952-7915(02)00354-0, 12088676.
28. Ullrich E, Menard C, Flament C, Terme M, Mignot G, Bonmort M, Plumas J, Chaperot L, Chaput N, Zitvogel L. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev 2008, 19:79-92. 10.1016/j.cytogfr.2007.10.009, 18155952.
29. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002, 9:961-966. 10.1038/sj.cgt.7700535, 12522435.
30. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007, 4:e353. 10.1371/journal.pmed.0040353, 2222946, 18162040.
31. Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res 2009, 69:7713-7720. 10.1158/0008-5472.CAN-09-1013, 19773437.
32. Connolly JL, Rodgers SE, Clarke P, Ballard DW, Kerr LD, Tyler KL, Dermody TS. Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB. J Virol 2000, 74:2981-2989. 10.1128/JVI.74.7.2981-2989.2000, 111796, 10708412.
33. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994, 10:405-455. 10.1146/annurev.cb.10.110194.002201, 7888182.
34. Natarajan K, Singh S, Burke TR, Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci USA 1996, 93:9090-9095. 10.1073/pnas.93.17.9090, 38600, 8799159.
35. Marcato PSM, Lee P. Connecting Reovirus oncolysis and Ras signalling. Cell cycle 2005, 4.
36. Garcia MA, Meurs EF, Esteban M. The dsRNA protein kinase PKR: virus and cell control. Biochimie 2007, 89:799-811. 10.1016/j.biochi.2007.03.001, 17451862.
37. Kumar A, Haque J, Lacoste J, Hiscott J, Williams BR. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc Natl Acad Sci USA 1994, 91:6288-6292. 10.1073/pnas.91.14.6288, 44186, 7912826.
38. Zhang P, Samuel CE. Protein kinase PKR plays a stimulus- and virus-dependent role in apoptotic death and virus multiplication in human cells. J Virol 2007, 81:8192-8200. 10.1128/JVI.00426-07, 1951329, 17522227.
39. Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: Viral Therapy for Cancer 'as Nature Intended'. Clin Oncol (R Coll Radiol) 2008,
40. Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010,
41. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM, Lee PW. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003, 63:348-353.
42. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006, 14:361-370. 10.1016/j.ymthe.2006.05.008, 16905462.
43. Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther 2010, 17:158-170. 10.1038/gt.2009.161, 20016540.
44. O'Donnell SM, Hansberger MW, Connolly JL, Chappell JD, Watson MJ, Pierce JM, Wetzel JD, Han W, Barton ES, Forrest JC, et al. Organ-specific roles for transcription factor NF-kappaB in reovirus-induced apoptosis and disease. J Clin Invest 2005, 115:2341-2350. 1184036, 16100570.
45. Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, Thompson J, Willmon C, Barber GN, Chester J, et al. Use of Biological Therapy to Enhance Both Virotherapy and Adoptive T-Cell Therapy for Cancer. Mol Ther 2008,
46. White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008,